Rebière, V., Maajem, M., Le Calloch, R., Raj, L., Le Bris, A.-S., Malou, M., Salmon, F., Quintin-Roué, I., Tempescul, A., Bourhis, D., Samaison, L., Saad, H., Salaun, P.-Y., Berthou, C., Ianotto, J.-C., Abgral, R., Eveillard, J.-R., 2022. Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.. https://doi.org/10.3389/fnume.2022.829138